Sweden · Delayed Price · Currency is SEK Oncopeptides AB Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 91% revenue growth and a 99% gross margin, driven by strong sales in Germany and Italy, while Spain lagged. Expansion into third-line treatment and glioblastoma, plus a SEK 200 million rights issue, position the company for further growth.
-
Plans to expand Pepaxti's indication to third-line multiple myeloma in Europe could double the addressable patient population and treatment cycles, supported by strong OCEAN study data. Regulatory submission is expected soon, with no change to the 2027 cashflow-positive target.
-
Q4 2025 sales grew 88% year-over-year, led by Italy, but Spain's doctor strike and German market challenges delayed profitability expectations to 2027. Strategic cost optimization, regional focus, and global partnerships are underway, with glioblastoma R&D prioritized.
Fiscal Year 2025
-
Net sales more than doubled year-over-year, driven by strong performance in Italy and robust gross margins, though growth in Germany and Spain was hampered by market access issues and external disruptions. A SEK 200 million rights issue will fund continued commercialization and pipeline expansion, with a focus on glioblastoma.
-
Strong sales growth and expanding European market access are underpinned by Pepaxti's unique clinical profile and real-world efficacy. The pipeline features next-generation peptide drug conjugates and NK cell engagers, targeting oncology and autoimmune diseases, with global partnerships and preclinical progress supporting long-term growth.
-
Q3 2025 saw net sales surge 174% year-over-year, with strong growth in Italy and Spain and robust gross margins. A successful rights issue strengthened liquidity, and the company remains on track for profitability by end-2026, with global expansion and scientific recognition advancing.
-
Celebrating 25 years, the company is expanding rapidly by commercializing Pepaxti for multiple myeloma in Europe, achieving strong sales growth and inclusion in treatment guidelines. Strategic direct sales in key markets and partnerships elsewhere support a goal of profitability by end-2026.
-
Q2 2025 saw net sales rise 45% sequentially and 135% year-over-year, with strong growth in Germany, Spain, and Italy. A SEK 150 million rights issue was announced to support operations and reach cash flow positivity by end-2026, as Pepaxti gains further clinical validation and market access.
-
Q1 2025 saw net sales nearly triple year-over-year, led by strong growth in Germany, Spain, and Italy, with a solid cash position and clear path to profitability by end of 2026. Key milestones included Italian reimbursement, FDA progress, and advancing Japan partnership.
Fiscal Year 2024
-
Q4 2024 saw revenue of SEK 9.9 million and a 35% increase in European sales, with Germany leading growth and Spain and Italy expanding access. Cash reserves of SEK 179 million support the goal of cash flow positivity by 2026, contingent on sales and new partnerships.
-
Q3 2024 saw revenue growth year-over-year, driven by strong performance in Spain and ongoing expansion in key European markets, though German and Greek sales lagged. Cost discipline improved margins, and profitability is targeted for 2026, with SEK 250 million in cash at quarter-end.
-
Q2 2024 revenue grew 60% sequentially, driven by Germany and the launch in Spain. Cost control measures and a successful rights issue support the goal of profitability by 2026, with further European expansion and pipeline progress underway.